BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Innovative Gene Profiling - Max Planck Institute for Medical Research And Axaron Bioscience AG Conclude Service Contract


10/19/2005 5:09:49 PM

Heidelberg, Germany, January 26, 2004 - The Max Planck Institute for Medical Research, Heidelberg, and Axaron Bioscience AG have inked a service contract covering the application of Axaron's Axaminer technology, a method enabling gene expression profiling at the cellular level for bioinformatic evaluation.

Axaron's Axaminer technology will be used at the Heidelberg MPI in conjunction with a project aimed at analyzing the molecular processes of glutamate-mediated signal transduction. As Professor Peter H. Seeburg, Director of the Department of Molecular Neurobiology at the Heidelberg MPI explains: "We are hoping these investigations will lead to a better understanding of neurological diseases such as stroke, for example."

Axaminer, an Axaron service for cell type-specific transcription profiling of cells isolated from complex tissues and organs, comprises four integrated modules: specific cell labeling, automated cell isolation using laser microdissection, the isolation and amplification of tiny amounts of RNA, as well as subsequent transcription profiling. The technology is offered either as a full service or tailored solution and allows observations of molecular processes at the cellular level that would not be possible using existing analytical methods.

Media Contact:
Alexander Pschera
Axaron Bioscience AG
Im Neuenheimer Feld 515
69120 Heidelberg
Tel.: 06221 454-705
Fax: 06221 454-776
Email: Alexander.pschera@axaron.com
www.axaron.com

Axaron Bioscience AG is a Heidelberg-based biotechnology company which pioneers innovative therapies for neurodegenerative diseases such as stroke or Parkinson's. The company capitalizes on its uniquely integrated functional genomics and proteomics technology platform and its world-leading network of expert partners in the CNS field. Axaminer is based on Axaron's proprietary technology and enables gene expression profiling at a cellular level. The Axaminer technology comprises four integrated modules offered as a full service or tailor-made solution to pharmaceutical companies. For further information please visit www.axaron.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES